December 2024

ZYNLONTA in combination with glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate Safety data show no dose-limiting toxicities (DLTs), no high-grade cytokine release syndrome (CRS) or high-grade immune effector cell-associated neurotoxicity syndrome (ICANS) across

CHICAGO, Dec. 11, 2024 /PRNewswire/ — May River Capital, a Chicago-based lower middle-market private equity firm, and its portfolio company, RLE Technologies, today announced the acquisition of NDSL Group Ltd., manufacturer of Cellwatch and leading battery monitoring and management solutions

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: